Literature DB >> 19395026

OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.

Thea Kristin Våtsveen1, Erming Tian, Stine H Kresse, Leonardo A Meza-Zepeda, Ana Gabrea, Oleg Glebov, Hong Yan Dai, Anders Sundan, W Michael Kuehl, Magne Børset.   

Abstract

Multiple myeloma can be classified into hyperdiploid (HRD) (with 48-74 chromosomes) and non-hyperdiploid tumors (usually with immunoglobulin heavy chain translocations). The OH-2 human myeloma cell line (HMCL) retains the same HRD genotype as the primary tumor, with extra copies of chromosomes 3, 7, 15, 19, and 21. Both OH-2 and primary cells have a complex secondary translocation in which the IGK 3' enhancer is inserted between MYC and MAFB, resulting in dysregulation of both oncogenes. OH-2 provides a unique example of an HMCL and the corresponding primary tumor that are shown to share the same HRD genotype.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19395026      PMCID： PMC6944273          DOI： 10.1016/j.leukres.2009.03.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  23 in total

1.  Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique.

Authors:  H Avet-Loiseau; A Daviet; C Brigaudeau; E Callet-Bauchu; C Terré; M Lafage-Pochitaloff; F Désangles; S Ramond; P Talmant; R Bataille
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Cell lines of hyperdiploid myeloma, are we there yet?

Authors:  Wee J Chng; Rafael Fonseca
Journal:  Br J Haematol       Date:  2007-11-19       Impact factor: 6.998

4.  Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas.

Authors:  Leonardo A Meza-Zepeda; Stine H Kresse; Ana H Barragan-Polania; Bodil Bjerkehagen; Hege O Ohnstad; Heidi M Namløs; Junbai Wang; Bjørn E Kristiansen; Ola Myklebost
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

5.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 6.  Genetic events in the pathogenesis of multiple myeloma.

Authors:  W J Chng; O Glebov; P L Bergsagel; W M Kuehl
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

7.  Genetic aberrations and survival in plasma cell leukemia.

Authors:  R E Tiedemann; N Gonzalez-Paz; R A Kyle; R Santana-Davila; T Price-Troska; S A Van Wier; W J Chng; R P Ketterling; M A Gertz; K Henderson; P R Greipp; A Dispenzieri; M Q Lacy; S V Rajkumar; P L Bergsagel; A K Stewart; R Fonseca
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

8.  Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2.

Authors:  N Jackson; J Lowe; J Ball; E Bromidge; N R Ling; S Larkins; M J Griffith; I M Franklin
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

9.  Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells.

Authors:  Torstein Baade Ro; Randi Utne Holt; Anne-Tove Brenne; Henrik Hjorth-Hansen; Anders Waage; Oyvind Hjertner; Anders Sundan; Magne Borset
Journal:  Oncogene       Date:  2004-04-15       Impact factor: 9.867

10.  Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.

Authors:  Amel Dib; Timothy R Peterson; Laura Raducha-Grace; Adriana Zingone; Fenghuang Zhan; Ichiro Hanamura; Bart Barlogie; John Shaughnessy; W Michael Kuehl
Journal:  Cell Div       Date:  2006-10-18       Impact factor: 5.130
View more
  5 in total

1.  Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients.

Authors:  Christoph Rampa; Erming Tian; Thea Kristin Våtsveen; Glenn Buene; Tobias Schmidt Slørdahl; Magne Børset; Anders Waage; Anders Sundan
Journal:  Biomark Res       Date:  2014-04-09

2.  Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.

Authors:  Alexey Zatula; Aida Dikic; Celine Mulder; Animesh Sharma; Cathrine B Vågbø; Mirta M L Sousa; Anders Waage; Geir Slupphaug
Journal:  Oncotarget       Date:  2017-03-21

3.  MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.

Authors:  Ya-Wei Qiang; Shiqiao Ye; Yuhua Huang; Yu Chen; Frits Van Rhee; Joshua Epstein; Brian A Walker; Gareth J Morgan; Faith E Davies
Journal:  BMC Cancer       Date:  2018-07-06       Impact factor: 4.430

4.  Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.

Authors:  Esten N Vandsemb; Helena Bertilsson; Pegah Abdollahi; Øystein Størkersen; Thea Kristin Våtsveen; Morten Beck Rye; Torstein Baade Rø; Magne Børset; Tobias S Slørdahl
Journal:  J Transl Med       Date:  2016-03-15       Impact factor: 5.531

5.  Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.

Authors:  K K Starheim; T Holien; K Misund; I Johansson; K A Baranowska; A-M Sponaas; H Hella; G Buene; A Waage; A Sundan; G Bjørkøy
Journal:  Blood Cancer J       Date:  2016-07-15       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.